Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Takeda hikes annual profit forecast by a third after second-quarter profit jump

      Takeda hikes annual profit forecast by a third after second-quarter profit jump

      Medical Dialogues Bureau1 Nov 2018 9:05 AM IST
      TOKYO: Japan's Takeda Pharmaceutical Co Ltd has boosted its annual operating profit outlook by a third after second-quarter earnings surged on strong...
      Merck India Charitable Trust Scholarship program, launched in Bengaluru

      Merck India Charitable Trust Scholarship program, launched in Bengaluru

      Medical Dialogues Bureau1 Nov 2018 9:00 AM IST
      Bengaluru: Merck a leading science and technology company, has recently launched the Merck India Charitable Trust Scholarship (MICT) at an event where...
      Dr Reddys gets 8 observations from USFDA for Duvvada plant

      Dr Reddy's gets 8 observations from USFDA for Duvvada plant

      Medical Dialogues Bureau31 Oct 2018 5:17 PM IST
      New Delhi: Dr Reddy's Laboratories Tuesday said US health regulator has issued eight observations after inspecting its formulations plant at Duvvada,...
      Glenmark gets USFDA nod for generic Derma-Smoothe Topical Oil

      Glenmark gets USFDA nod for generic Derma-Smoothe Topical Oil

      Medical Dialogues Bureau31 Oct 2018 5:16 PM IST
      New Delhi: Glenmark Pharmaceuticals Tuesday said it has received final approval from the US health regulator for the generic version of Derma-Smoothe...
      Pfizer lowers revenue forecast on strong dollar, supply issues

      Pfizer lowers revenue forecast on strong dollar, supply issues

      Medical Dialogues Bureau31 Oct 2018 5:15 PM IST
      U.S. drugmaker Pfizer Inc cut the top end of its full-year revenue forecast range on Tuesday, citing a stronger dollar and lower revenue from its...
      AstraZeneca sells some rights to Nexium, Vimovo to Grunenthal

      AstraZeneca sells some rights to Nexium, Vimovo to Grunenthal

      Medical Dialogues Bureau31 Oct 2018 5:15 PM IST
      LONDON: AstraZeneca said it would sell the European rights to acid-reflux medicine Nexium to Grunenthal for an upfront $700 million and future...
      Monsanto India Q2 profit at Rs 24 cr, revenue up 33% at Rs 133.49 cr

      Monsanto India Q2 profit at Rs 24 cr, revenue up 33% at Rs 133.49 cr

      Medical Dialogues Bureau31 Oct 2018 5:14 PM IST
      New Delhi: Seed firm Monsanto India Monday reported a net profit of Rs 24.09 crore for the quarter ended September 2018. Its net loss stood at Rs 6.39...
      Eli Lilly buys Rs 736 Crore stake in gene-silencing drug firm Dicerna

      Eli Lilly buys Rs 736 Crore stake in gene-silencing drug firm Dicerna

      Medical Dialogues Bureau30 Oct 2018 4:43 PM IST
      Dicerna will receive an upfront payment of $100 million, as well as an equity investment of $100 million at a premium. New Delhi: Eli Lilly and...
      Granules gets 2 observation by USFDA for U.S Unit

      Granules gets 2 observation by USFDA for U.S Unit

      Medical Dialogues Bureau30 Oct 2018 10:48 AM IST
      New Delhi: Pharma firm Granules through a recent regulatory filing announced its US subsidiary has received two observations from the US health...
      Cipla gets USFDA approval for Metoprolol ER Tablets

      Cipla gets USFDA approval for Metoprolol ER Tablets

      Medical Dialogues Bureau30 Oct 2018 9:25 AM IST
      Mumbai: Cipla Limited announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Metoprolol ER Tablets 50mg,...
      TherapeuticsMD gets FDA approval of Bijuva drug

      TherapeuticsMD gets FDA approval of Bijuva drug

      Medical Dialogues Bureau30 Oct 2018 9:20 AM IST
      New Delhi: TherapeuticsMD, Inc. an innovative women’s healthcare company, has recently announced that the United States Food and Drug Administration...
      Takeda proposes sale of Shire drug to gain European approval

      Takeda proposes sale of Shire drug to gain European approval

      Medical Dialogues Bureau30 Oct 2018 9:00 AM IST
      New Delhi: Takeda Pharmaceutical has proposed to European regulators it could sell a Shire treatment in development due to concerns of overlap in...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok